ProMIS Neurosciences Inc. (PMN:NASDAQ), a clinical-stage biotechnology company developing antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, published an investor Q&A in November 2026 outlining the scientific rationale behind its lead candidate, PMN310. The update followed disappointing Phase 2 results for Acumen Pharmaceuticals Inc. (ABOS:NASDAQ) and its investigational Alzheimer’s disease antibody, sabirnetug.
ProMIS emphasized differences in the two candidates' antibody designs, target selectivity, and interim safety findings. The company continues to expect unblinded 12-month topline results from its PRECISE-AD Phase 1b trial in the first quarter of 2027.
Key Investor Takeaways
- ProMIS published an investor Q&A outlining how PMN310's selectivity for toxic amyloid-beta oligomers and IgG1 antibody design differ from Acumen's sabirnetug.
- Roth Capital maintained a Buy rating on November 2 but lowered its price target on ProMIS to US$15 from US$29 following Acumen's Phase 2 results.
- ProMIS reported US$53.4 million in cash and short-term investments as of June 30, 2026, and said its cash position provided runway through 2027.
- The six-month blinded interim analysis of PRECISE-AD evaluated 136 participants and showed no cases of ARIA-E. Acumen reported an approximately 10% ARIA-E incidence in its separate sabirnetug trial.
- ProMIS expects to report third-quarter 2026 financial results and provide a corporate update on November 12.
- The next major anticipated clinical milestone is the unblinded 12-month topline readout from PRECISE-AD, expected in Q1 2027.
Latest News and Upcoming Catalysts
On November 3, 2026, ProMIS announced that it will report third-quarter financial results and provide a business update on November 12. The company also scheduled an investor conference call and webcast for 4:30 p.m. ET that day. The announcement referenced the company's recent PMN310 scientific and clinical Q&A, which addresses the implications of Acumen's Phase 2 results for ProMIS's development program.
The next major clinical milestone remains the expected Q1 2027 release of unblinded 12-month topline data from PRECISE-AD, ProMIS's Phase 1b study of PMN310 in patients with early Alzheimer's disease. The company said in its Q&A that the Acumen results do not change its development plans or anticipated readout timing.
How PMN310 Differs From Acumen's Sabirnetug
Acumen announced on October 30 that its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) did not meet its primary endpoint or key secondary efficacy endpoints. The study evaluated changes in cognitive and functional decline in people with early Alzheimer's disease. Acumen also reported that sabirnetug was generally well tolerated, with amyloid-related imaging abnormalities-edema (ARIA-E) observed in approximately 10% of treated participants. Following the results, Acumen said it planned to discontinue sabirnetug development and evaluate strategic options.
The results prompted a response from ProMIS, which outlined three differences between sabirnetug and its own investigational antibody in the November investor Q&A.
On November 2, 2026, Boobalan Pachaiyappan of Roth Capital lowered the price target on ProMIS to US$15 from US$29 while maintaining a "Buy" rating.
Target selectivity: ProMIS says PMN310 was engineered to bind toxic, misfolded amyloid-beta oligomers while avoiding monomers, fibrils, and amyloid plaques. The company describes sabirnetug as having a broader binding profile, including plaque binding. ProMIS's central scientific hypothesis is that toxic soluble oligomers, rather than plaques alone, are important contributors to Alzheimer's-related neuronal damage and cognitive decline.
Antibody design: PMN310 uses an IgG1 antibody backbone. ProMIS says this design is intended to both neutralize toxic oligomers and potentially recruit microglia, immune cells in the brain, to help clear them. Sabirnetug uses an IgG2 backbone, which ProMIS describes as having reduced immune effector function and a greater emphasis on neutralization rather than immune-mediated clearance.
Interim safety findings: ProMIS highlighted the absence of ARIA-E in the six-month blinded interim analysis of PRECISE-AD, compared with the approximately 10% incidence reported by Acumen for sabirnetug. The ProMIS analysis evaluated 136 participants across all APOE genotypes. The company said the findings support its approach to targeting oligomers while avoiding plaques.
These findings are from separate clinical trials and should not be interpreted as a direct comparison of the candidates. ProMIS also acknowledged in its Q&A that clinical efficacy for PMN310 has yet to be established. Its upcoming 12-month topline results are expected to provide additional safety, biomarker, and cognitive-outcome data.
The PRECISE-AD Trial Status
ProMIS reported approximately US$53.4 million in cash and short-term investments as of June 30, 2026. In its Q2 financial results, the company said this position provided runway through 2027, beyond its next major anticipated catalyst. The PRECISE-AD Phase 1b trial enrolled 144 participants with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease. The randomized, double-blind, placebo-controlled study evaluates PMN310 at three dose levels, administered monthly over 12 months.
The six-month interim analysis included 136 safety-evaluable participants. ProMIS reported no ARIA-E cases across the evaluated APOE genotypes. The company also reported early movement in disease-related biomarkers, including reductions in plasma pTau217 and cerebrospinal fluid MTBR-tau243 in portions of the pooled study population. The company cautioned that these blinded biomarker observations do not establish efficacy.
The trial remains blinded, and ProMIS expects unblinded 12-month topline results in Q1 2027.
Analyst Says Extrapolating Acumen Results to ProMIS Is 'Premature' but Maintains Buy
On November 2, 2026, Boobalan Pachaiyappan of Roth Capital lowered the price target on ProMIS to US$15 from US$29 while maintaining a "Buy" rating.
The firm said some negative read-through from Acumen's failed Phase 2 study was warranted, but that a one-for-one extrapolation to ProMIS was premature. The report also noted that, in a follow-up call, ProMIS management emphasized PMN310's conformational selectivity, plaque avoidance, and IgG1 backbone as differentiating features.
Earlier, on October 16, 2026, Raghuram Selvaraju of H.C. Wainwright & Co. also reiterated a "Buy" rating.
In August, three other analysts weighed in:
- On August 14, 2026, Eddie Hickman of Guggenheim reiterated a "Buy" rating and raised the price target from US$69 to US$100.
- On August 14, 2026, Jason McCarthy of Maxim Group reiterated a "Buy" rating and price target of US$35.
- On August 13, 2026, Keay Nakae of Chardan Capital reiterated a "Buy" rating and price target of US$33.
Ownership and Share Structure1
Institutions hold about 70.00% of ProMIS Neurosciences, while Management and insiders own approximately 11.90%, with retail investors accounting for the balance.
The largest disclosed holders are Janus Henderson Group (14.40%) and Ally Bridge Group (10.60%).
The company has roughly 8.97 million shares outstanding and a market capitalization of about US$31.57 million.
Insiders were buyers over the last six months, purchasing about 13596 shares, with no verified open-market sales in that window.
20 series of warrants remain outstanding. Public records show 3 historical share restructures.
Common Questions from Investors
What happened in Acumen's ALTITUDE-AD trial?
Acumen's Phase 2 trial of sabirnetug did not meet its primary endpoint or key secondary efficacy endpoints. The company said it plans to discontinue sabirnetug development and evaluate strategic options.
How does PMN310 differ from sabirnetug?
ProMIS says PMN310 selectively targets toxic amyloid-beta oligomers, avoids plaques, and uses an IgG1 backbone designed to support both neutralization and immune-mediated clearance. Sabirnetug uses an IgG2 backbone and has a broader binding profile, according to ProMIS.
What were the six-month interim safety findings for PMN310?
ProMIS reported no ARIA-E cases among the 136 participants evaluated in its six-month blinded interim analysis. These findings do not establish clinical efficacy.
When will ProMIS report its next clinical results?
The company expects unblinded 12-month topline results from PRECISE-AD in Q1 2027.
How much cash did ProMIS report?
ProMIS reported approximately US$53.4 million in cash and short-term investments as of June 30, 2026, which the company said provided runway through 2027.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Ownership and Share Structure Information
Ownership percentages, named holders, share count, market capitalization, and the 52-week range for ProMIS Neurosciences were compiled from company public filings and investor materials, exchange notices, insider-trade reports (SEDI / equivalent), and third-party data providers. Figures are as of 2026-11-05 unless a source was dated earlier. Pie slices are normalized to 100% of basic shares outstanding; retail is the residual after disclosed institutions, management, insiders, and strategic holders. Warrant terms are current outstanding series only. Restructures are historical consolidations, splits, and symbol or name changes. Insider buying and selling covers open-market trades from the prior six months through 2026-11-05 and excludes option exercises. These are public-source estimates and can differ from a later official register.
